1. Home
  2. QNRX vs GDTC Comparison

QNRX vs GDTC Comparison

Compare QNRX & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

HOLD

Current Price

$7.06

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$0.98

Market Cap

10.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNRX
GDTC
Founded
2018
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.2M
10.4M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
QNRX
GDTC
Price
$7.06
$0.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
901.6K
16.6K
Earning Date
05-07-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.25
$0.68
52 Week High
$41.80
$3.68

Technical Indicators

Market Signals
Indicator
QNRX
GDTC
Relative Strength Index (RSI) 67.72 41.45
Support Level $7.00 $0.73
Resistance Level $8.25 $1.08
Average True Range (ATR) 0.52 0.08
MACD -0.01 -0.00
Stochastic Oscillator 76.21 6.57

Price Performance

Historical Comparison
QNRX
GDTC

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: